Discover how scientists identified the 66-68 kDa methotrexate-binding protein HSC70 in leukemia cells and its role in chemotherapy resistance.
In the relentless battle against cancer, scientists have long been fascinated—and frustrated—by how cancer cells evolve to resist our most powerful drugs. This phenomenon of drug resistance has turned curable cancers into terminal diagnoses and effective medications into ineffective treatments.
Nowhere is this challenge more apparent than in leukemia treatment, where the chemotherapy drug methotrexate (MTX) has saved countless lives but eventually fails when cancer cells learn to evade its effects.
For decades, researchers knew that something was preventing MTX from reaching its target in resistant cells, but they couldn't identify the culprit. This is the story of how scientists discovered a previously overlooked protein accomplice—a 66-68 kDa molecular helper that plays a surprising role in shuttling MTX into cells, and how its modification may hold the key to overcoming treatment-resistant cancers 1 2 .
To understand this discovery, we must first understand how methotrexate works. MTX is a chemotherapy drug used since the 1940s to treat various cancers, including leukemia, as well as autoimmune diseases like rheumatoid arthritis. It works by mimicking folic acid, a vitamin essential for cell division and growth.
MTX impersonates folate and inhibits dihydrofolate reductase (DHFR), which is essential for folate metabolism. With DHFR disabled, the cell cannot produce nucleotides, DNA replication stalls, and the rapidly dividing cancer cell dies 2 .
Researchers studying cisplatin-resistant leukemia cells observed extraordinary collateral resistance to MTX—sometimes as much as 25,000-fold higher than their sensitive counterparts . Clearly, something dramatic was preventing MTX from entering these cells, but none of the known resistance mechanisms could explain it.
The trail began with an intriguing observation. When researchers compared sensitive L1210 murine leukemia cells with their cisplatin-resistant counterparts (L1210/DDP), they noticed something peculiar: the resistant cells lacked a tyrosine-phosphorylated, membrane-associated protein weighing 66-68 kilodaltons (kDa) that was present in the sensitive cells 1 2 .
Using photoaffinity labeling, scientists had identified several proteins that seemed to bind MTX during its journey into the cell: 66-68 kDa, 48 kDa, 38 kDa, and 21 kDa proteins. In resistant cells, however, the photoaffinity label only associated with the 66-68 kDa protein and didn't progress to the other proteins, suggesting a transport blockade at this initial step .
The mysterious 66-68 kDa protein appeared to be a critical gatekeeper for MTX entry, and its phosphorylation status seemed to differentiate functioning from non-functioning transport systems.
To identify the mysterious protein, researchers designed an elegant series of experiments that combined affinity purification with modern proteomic techniques 1 2 .
The team grew both sensitive (L1210/0) and resistant (L1210/DDP) murine leukemia cells under controlled conditions, then harvested them for analysis.
Since the mysterious protein was membrane-associated, researchers carefully isolated the membrane fractions from both cell types.
The scientists used MTX-agarose beads to selectively capture proteins that bind MTX.
The purified protein was separated by electrophoresis, revealing a single band at 66-68 kDa. This band was treated with trypsin to chop it into peptide fragments.
Peptide fragments were analyzed using mass spectrometry, yielding two partial peptide sequences: VEIIANDQ and VTNAVVTVPAYFNDSQRQA.
Researchers used the TBLASTN function to search mouse genome databases, identifying a single gene: HSPa8, which codes for the heat shock family protein HSC70.
Additional experiments confirmed HSC70 indeed bound MTX, including MTX-agarose binding assays, cloning and expression of HSC70, and domain mapping.
| Step | Technique | Purpose | Outcome |
|---|---|---|---|
| 1. Protein Purification | Affinity chromatography | Isolate MTX-binding proteins | Single 66-68 kDa protein band |
| 2. Protein Digestion | Trypsin treatment | Chop protein into fragments | Multiple peptide fragments |
| 3. Fragment Analysis | Mass spectrometry | Determine amino acid sequences | Two sequences: VEIIANDQ and VTNAVVTVPAYFNDSQRQA |
| 4. Gene Identification | TBLASTN database search | Find gene encoding these sequences | HSPa8 gene identified |
| 5. Validation | MTX-agarose binding + Western blot | Confirm MTX binds to HSC70 | HSC70 binds MTX in multiple cell types |
The experimental results were clear and compelling. The HSPa8 gene produces HSC70, a member of the heat shock protein 70 (HSP70) family. These proteins are typically known as chaperones that help other proteins fold correctly and avoid aggregation, especially under cellular stress. Finding that HSC70 also binds MTX was unexpected and revealed a previously unknown function for this protein 1 2 .
When researchers treated sensitive cells with genistein (a tyrosine kinase inhibitor), they became more resistant to MTX, similar to the resistant cells. This suggested that phosphorylation of HSC70 at tyrosine residues was essential for its ability to help transport MTX into cells 5 .
| Property | Description | Significance |
|---|---|---|
| Molecular Weight | 66-68 kDa | Matches size of previously observed unknown protein |
| Cellular Location | Membrane-associated | Positioned to participate in transport |
| Phosphorylation | Tyrosine-phosphorylated in sensitive cells | Modification affects MTX binding ability |
| Conservation | DnaK (bacterial equivalent) also binds MTX | Evolutionarily ancient function |
| Binding Domain | ATPase domain | Suggests possible mechanism for MTX binding |
| Interaction Partner | Colocalizes with reduced folate carrier (RFC) | May facilitate MTX transport |
The identification of HSC70 as an MTX-binding protein has implications that extend far beyond understanding resistance in murine leukemia cells:
Understanding this mechanism could lead to strategies to prevent or reverse resistance, potentially restoring drug efficacy.
HSC70 modification might explain acquired resistance in rheumatoid arthritis patients treated with low-dose MTX.
Knowing HSC70's binding domain might enable design of modified MTX molecules that bypass resistance mechanisms.
Detecting HSC70 phosphorylation status might predict MTX response, enabling personalized treatment approaches.
This discovery reveals a previously unknown function for HSC70—participating in drug transport—suggesting that molecular chaperones may have moonlighting functions beyond their traditional roles.
References will be listed here